Glaukos (GKOS) Expected to Announce Earnings on Wednesday

Glaukos (NYSE:GKOS) will likely be announcing its Q1 2026 results after the market closes on Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $136.8880 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 4:30 PM ET.

Glaukos (NYSE:GKOS) last announced its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The company had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The company’s revenue for the quarter was up 35.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.40) EPS. On average, analysts expect Glaukos to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Glaukos Trading Down 2.1%

Shares of GKOS opened at $121.99 on Wednesday. Glaukos has a 1-year low of $73.16 and a 1-year high of $130.23. The firm’s 50-day moving average price is $112.31 and its 200-day moving average price is $106.11. The company has a current ratio of 4.69, a quick ratio of 4.06 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $7.14 billion, a price-to-earnings ratio of -37.42 and a beta of 0.78.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of research analyst reports. UBS Group upped their target price on Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, December 23rd. Wells Fargo & Company increased their price objective on Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Wall Street Zen downgraded Glaukos from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. BTIG Research reiterated a “buy” rating and issued a $131.00 price objective on shares of Glaukos in a report on Wednesday, February 18th. Finally, Stifel Nicolaus increased their price objective on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and a consensus target price of $133.69.

Insider Transactions at Glaukos

In related news, COO Joseph E. Gilliam sold 10,498 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $127.68, for a total value of $1,340,384.64. Following the sale, the chief operating officer owned 92,366 shares in the company, valued at $11,793,290.88. This represents a 10.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Alex R. Thurman sold 2,511 shares of the company’s stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $106.46, for a total value of $267,321.06. Following the completion of the sale, the chief financial officer owned 41,967 shares in the company, valued at $4,467,806.82. The trade was a 5.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,155 shares of company stock worth $5,506,094 in the last ninety days. 6.40% of the stock is owned by company insiders.

Institutional Trading of Glaukos

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC purchased a new stake in shares of Glaukos in the 4th quarter worth approximately $28,000. Smartleaf Asset Management LLC grew its stake in shares of Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 136 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Glaukos in the 4th quarter worth approximately $128,000. Van ECK Associates Corp grew its stake in shares of Glaukos by 24.2% in the 3rd quarter. Van ECK Associates Corp now owns 1,738 shares of the medical instruments supplier’s stock worth $142,000 after buying an additional 339 shares during the last quarter. Finally, Focus Partners Wealth grew its stake in shares of Glaukos by 6.9% in the 3rd quarter. Focus Partners Wealth now owns 2,714 shares of the medical instruments supplier’s stock worth $202,000 after buying an additional 176 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.